An inspiring journey shared about the power of the PARIS test in battling low-grade serous ovarian cancer. Cancer can plunge individuals into uncertainty and fear, but functional tumor testing like the PARIS® Test can offer a guiding light. This revolutionary approach not only sheds light on unique cancer characteristics but also becomes a critical tool in the fight against this rare adversary.
Read More
New Non-Small Cell Lung Cancer Study at Johns Hopkins University
Read More
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS® Test
Read More
Dana Farber Collaboration to Bring PARIS® Test to Patients with CNS Cancers
Read More
PARIS® Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer
Read More
Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing and 3D tumor cell culture.
Read More
Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting
Read More
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS® Test at 2021 ASCO Annual Meeting
Read More
SEngine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer
Read More